Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCS110 with Neoadjuvant Chemotherapy in HR+/HER2- Breast Cancer
NCT03285607Phase 1Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2018
- Primary completion
- Oct 2019
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of lacnotuzumab in Hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer (3 arms), sponsored by Washington University School of Medicine. Primary endpoint: Maximum Tolerated Dose at 28 days. Planned start Sep 2018; status: withdrawn.
02
Drugs
lacnotuzumab
03
Conditions
Hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer
Beyond the preview
Go deeper on NCT03285607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03285607.